SCHEMBL6012040

SCHEMBL6012040

O=Cc1ccc2noc(-c3cccc(Cl)c3)c2c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.73
KDM4E B2RXH2 5/20 0.73
POLB P06746 3/20 0.73
SMN1; SMN2 Q16637 3/20 0.73
MAPT P10636 3/20 0.73
MEN1 O00255 5/20 0.72
KMT2A Q03164 5/20 0.72
NPC1 O15118 2/20 0.72
IP6K1 Q92551 10/20 0.69
HPGD P15428 3/20 0.61
RAB9A P51151 1/20 0.61
PTK2B Q14289 1/20 0.61
IP6K2 Q9UHH9 9/20 0.51
IP6K3 Q96PC2 8/20 0.51
HTT P42858 2/20 0.51
LMNA P02545 1/20 0.51
GFER P55789 1/20 0.48
HSD17B10 Q99714 2/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4934034 0.84 ALDH1A1 (1.00) ALDH1A1KDM4EPOLBSMN1; SMN2MAPT
SCHEMBL31265142 0.84 KDM4E (0.73) ALDH1A1KDM4EPOLBSMN1; SMN2MAPT
SCHEMBL25352733 0.84 KDM4E (0.73) ALDH1A1KDM4EPOLBSMN1; SMN2MAPT
SCHEMBL30967420 0.82 IP6K1 (1.00) ALDH1A1KDM4EPOLBSMN1; SMN2MAPT
SCHEMBL25990902 0.81 ALDH1A1 (0.67) ALDH1A1KDM4EPOLBSMN1; SMN2MAPT
SCHEMBL1757999 0.79 ALDH1A1 (0.61) ALDH1A1KDM4EPOLBSMN1; SMN2MAPT
SCHEMBL29080634 0.78 ALDH1A1 (0.64) ALDH1A1KDM4EPOLBSMN1; SMN2MAPT
SCHEMBL6199027 0.76 KDM4E (1.00) ALDH1A1KDM4EPOLBSMN1; SMN2MAPT
SCHEMBL13208416 0.76 ALDH1A1 (0.57) ALDH1A1KDM4EPOLBSMN1; SMN2MAPT
SCHEMBL25991593 0.75 IP6K1 (0.81) ALDH1A1KDM4EPOLBSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067531-B2 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-27 US disclosed
US-20030199547-A1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives JANSSEN-CILAG S.A. (FR) 2003-10-23 US disclosed
EP-1322644-A1 FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINONE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2003-07-02 EP disclosed
WO-2002024687-A1 FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINONE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199547-A1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives FNTA, FNTB, RCE1 ALDH1A1 645/4885KDM4E 2224/4885POLB 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.